BioCentury | Apr 16, 2015
Distillery Therapeutics

Therapeutics: Wingless-type MMTV integration site family member 16 (WNT16)

...and in vitro testing of ellagic acid analogs identified a lead compound that targeted a WNT16...
...it in mouse models of colon cancer. TARGET/MARKER/PATHWAY: Wingless-type MMTV integration site family member 16 (WNT16...
BioCentury | Oct 30, 2014
Distillery Therapeutics

Indication: Musculoskeletal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease Musculoskeletal disease Wingless-type MMTV integration site family member 16B (WNT16B) Rodent studies suggest WNT16B could help prevent bone loss and consequent bone fractures. Loss-of-function...
BioCentury | Aug 30, 2012
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Wingless-type MMTV integration site family member 16B (WNT16B) Human tissue and mouse studies suggest inhibiting stromal WNT16B could help treat cancer. In tissue samples...
Items per page:
1 - 3 of 3